Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Androgens as anticancer agents)
21,472 results
  • Localization diagnosis of adrenocorticotrophic hormone-dependent Cushing's syndrome: two case reports and literature review. [Case Reports]
    Ann Palliat Med. 2022 Dec; 11(12):3804-3817.Qiu Y, Zhao H, … Li Q
  • CONCLUSIONS: The differentiation between CD and EAS should be comprehensively evaluated in combination with the medical history, function tests, pituitary MRI, and other tests. If the function test results are discordant or pituitary MRI shows the lesion diameter is less than 6 mm, BIPSS should be further performed to confirm the diagnosis. The lesions of EAS are complex and diverse, and it is necessary to pay attention to imaging examinations of the neck-to-pelvis to locate lesion and provide direction for subsequent treatment.
  • Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide. [Journal Article]
    JAMA Netw Open. 2022 12 01; 5(12):e2248135.Garcia-Argibay M, Hiyoshi A, … Montgomery S
  • CONCLUSIONS: This cohort study found that, while men receiving 5-ARI treatment showed a higher risk for dementia in the initial periods after starting treatment, the decreasing magnitude of the association over time suggested that the risk may be, entirely or in part, due to increased dementia detection among patients with benign prostate enlargement. Both finasteride and dutasteride were similarly associated with depression with a constant risk over time, while neither drug was associated with suicide. Prescribing clinicians and potential users should be aware of the possible risks for depression associated with 5-ARI use.
  • Tumor-derived OBP2A promotes prostate cancer castration resistance. [Journal Article]
    J Exp Med. 2023 Mar 06; 220(3)Jeong JH, Zhong S, … Luo JL
  • Androgen deprivation therapy (ADT) is a systemic therapy for advanced prostate cancer (PCa); although most patients initially respond to ADT, almost all cancers eventually develop castration-resistant PCa (CRPC). Currently, most research focuses on castration-resistant tumors, and the role of tumors in remission is almost completely ignored. Here, we report that odorant-binding protein (OBP2A) re…
  • Gender confirmation hormonal treatment use in young Polish transgender binary and non-binary persons. [Journal Article]
    Endokrynol Pol. 2022; 73(6):922-927.Gawlik A, Antosz A, … Grabski B
  • CONCLUSIONS: These treatments (including pubertal blocking) seem to be rarely commenced in Poland before the age of 18 years. In adults, treatment consists mostly of either testosterone or oestradiol, and cyproterone acetate and, more seldom, spironolactone are used as antiandrogens in persons assigned male at birth. In turn, gonadotropin-releasing hormone agonists are barely used at all. Specialists need to be more aware that withholding treatment in minors with gender dysphoria is not a health-neutral option. Gonadotropin-releasing hormone agonists should also be more often considered as an alternative to cyproterone acetate in the context of long-term safety.
New Search Next